Pipeline

Product Pipeline

MacroGenics has a diverse portfolio of product candidates with several clinical trials currently underway or planned for the near future.  Set forth below is the company's development pipeline.

 

Program (Target) Indication Global Partner Lead Optim. Pre-Clin. Phase 1 Phase 2 Phase 3
ONCOLOGY          
MGAH22 * (HER2) Solid Tumors *  *  *  *  * 
MGA271 ** (B7-H3) Solid Tumors *  *  *  *  * 
Multiple DARTs   Solid Tumors *  *  *  *  * 
DART mAb   Liquid Tumors *  *  *  *  * 
mAbs  (>70 Targets) Solid & Liq. Tumors *  *  *  *  * 
AUTOIMMUNE          
Teplizumab *** (CD3) T1D - Early Onset *  *  *  *  * 
T1D - At-Risk *  *  *  *  * 
DART **** (CD32BxCD79) Inflammation *  *  *  *  * 
Multiple DARTs   Autoimmune *  *  *  *  * 
INFECTIOUS DISEASES          
Mult. mAbs/DARTs ****  Emerging Diseases *  *  *  *  * 

*Green Cross has marketing rights in Korea only

**MacroGenics retains rights in N. America, Japan, Korea & India.
Servier has option to license rights in ROW.

***At Risk study sponsored by NIDDK/TrialNet

****Sponsored by NIH
Proprietary
Partnered

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Corporate Overview

Corporate Fact Sheet

Platform Fact Sheets

 DART
 Cancer Stem-like Cells
 Fc Optimization

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more